ALSO NOTED: Wyeth bullish on late-stage drug; Zeltia forms research arm; and much more...

> Wyeth is bullishly forecasting potential annual sales of the experimental drug bazedoxifene after analyzing late-stage data for osteoporosis and vasomotor symptoms of menopause. Report

> Wyeth has inked a $195 million licensing pact with the UK's Biotica for novel rapamycin analogs. Report

> Spain's Zeltia is creating a separate arm to pursue work in RNAi. The new unit, Sylentis, will explore gene silencing in ophthalmology and digestive systems. Release

> A subsidiary of Zeltia says that its independent data monitoring committee has approved a Phase III clinical trial of Yondelis for ovarian cancer. Report

> Roche has released new data demonstrating the effectiveness of Fuzeon in treatment-experienced HIV patients. Report

> The FDA has fast-tracked Agennix's talactoferrin alfa for cancer/diabetic foot ulcers. Report

> The FDA has approved Berlex's birth control pill Yaz for a new indication: premenstrual dysphoric disorder. Report

> MedImmune has taken its quest to sue Genentech in a patent violation case directly to the Supreme Court. Report

> Inspire Pharmaceuticals says it is continuing talks with the FDA over Prolacria for dry-eye. The agency said earlier this year that it had insufficient data on the drug's efficacy for an approval. Article

And Finally... Can the FDA regulate nanotech effectively? A former FDA official doesn't think so. Article